AL-001 / Anlong Biopharma - LARVOL DELTA

Preclinical evaluation of AL-001, a gene therapy for wet age-related macular degeneration. (PubMed, Front Genet) - "Suprachoroidal administration of AL-001 is well tolerated and provides durable, targeted aflibercept expression with pronounced antiangiogenic efficacy. These results support AL-001 as a promising, long-acting therapeutic candidate for wAMD."

Journal • Preclinical • Age-related Macular Degeneration • Gene Therapies • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Beijing Anlong Biopharmaceutical Co., Ltd.

New P2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD (clinicaltrials.gov) - P=N/A | N=21 | Recruiting | Sponsor: Beijing Anlong Biopharmaceutical Co., Ltd.

New trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD (clinicaltrials.gov) - P1/2 | N=21 | Active, not recruiting | Sponsor: Beijing Anlong Biopharmaceutical Co., Ltd.

New P1/2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration